VTRS logo

VTRS
Viatris Inc

3,786
Mkt Cap
$19.32B
Volume
2.27M
52W High
$17.53
52W Low
$8.19
PE Ratio
-63.55
VTRS Fundamentals
Price
$16.59
Prev Close
$16.34
Open
$16.42
50D MA
$14.66
Beta
0.80
Avg. Volume
9.42M
EPS (Annual)
-$3.00
P/B
1.31
Rev/Employee
$476,440.00
$27,822.22
Loading...
Loading...
News
all
press releases
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.
News Placeholder
More News
News Placeholder
Here's Why Viatris (VTRS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
News Placeholder
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for...
News Placeholder
Why Viatris (VTRS) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
News Placeholder
Why Viatris (VTRS) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
News Placeholder
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Theravance Q1 earnings top estimates as collaboration revenues grow, while restructuring and cost cuts aim to drive $60-$70M annualized cash flow.
News Placeholder
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference Viatris to Present at the Bank of America Securities 2026 Healthcare Conference PR Newswire PITTSBURGH, May 7, 2026...
News Placeholder
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China
VTRS beats Q1 estimates as revenues climb 8% on strong Greater China and brands sales, while management reaffirms 2026 guidance.
News Placeholder
Here's What Key Metrics Tell Us About Viatris (VTRS) Q1 Earnings
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
News Placeholder
Viatris (VTRS) Q1 Earnings and Revenues Surpass Estimates
Viatris (VTRS) delivered earnings and revenue surprises of +13.46% and +4.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available